🍭 The Sweetener Stack

Editors’ Note: Our website features a healthspan-focused job board, an archive of past newsletters, a growing dictionary of terms we’ve highlighted in previous editions and more to come!

Visit us at: https://stacked-health.com/

Or copy and paste this link to others: {{rp_refer_url}}

The professionals pulling ahead aren't working more. They're using Claude.

Our free guide will show you how to:

Transform your workflow with AI and stay ahead of the curve with this comprehensive guide to using Claude at work.

Get The Free Guide

Every major sweetener except stevia was discovered by a chemist ignoring lab safety. A century of accidents built a $10B+ category that diet culture scaled, keto reshaped, and GLP-1s are now quietly shrinking. 

Accidents

The history of alternative sweeteners is a history of chemists tasting things they shouldn't have. Saccharin arrived in 1879 when a Johns Hopkins researcher working on coal tar derivatives noticed his bread tasted sweet and traced it back to his unwashed hands. Cyclamate came in 1937 from a graduate student who set his cigarette down on a lab bench. Aspartame was discovered in 1965 by a chemist synthesizing an anti-ulcer drug who licked his finger to pick up a piece of paper. Sucralose, in 1976, is the best one: a foreign researcher misheard an instruction to "test" a chlorinated sugar compound as "taste."

None of these molecules were designed to be sweet. Sweetness was found, then commercialized. The exceptions prove the rule: stevia was used in Paraguay for centuries and industrialized by Japan in the 1970s, and monk fruit extract came through the traditional-use route too. The engineered-on-purpose generation is only arriving now, which we'll get to.

What actually built the market

Demand came in waves, and each wave selected for a different product. Wartime sugar shortages made saccharin a pantry staple decades before anyone counted calories. Midcentury diet culture built the tabletop-packet and diet-soda economy on cyclamate and saccharin, then aspartame after cyclamate was banned in 1969 on rat bladder tumor data that never replicated well and was later contested. The low-carb and keto eras of the 2000s and 2010s wanted bulk, not just sweetness, and that requirement is what elevated sugar alcohols like erythritol and xylitol, since intense sweeteners can't replace sugar's volume in a cookie. Sugar taxes and reformulation mandates abroad pushed the packaged-food industry in the same direction.

Each wave also produced a scare cycle. Cyclamate was banned. Saccharin carried a cancer warning label for two decades until the rat mechanism was shown not to apply to humans and it was delisted in 2000. Aspartame has survived more studies than any food additive in history. The pattern worth internalizing: initial panic, decades of accumulating data, quiet exoneration. The pattern has run in that direction every time so far. Erythritol is the first case where the arrow may point the other way.

How the referees work

Two regulatory concepts explain most sweetener headlines. The first is the ADI, the acceptable daily intake, set with a large safety margin below doses showing any effect in animals. For aspartame, an average adult would need well over a dozen diet sodas daily to reach it. The second is the difference between hazard and risk. When IARC classified aspartame as "possibly carcinogenic" in 2023, it was answering the question "could this cause harm under any conceivable exposure," a category that includes aloe vera. The FAO/WHO committee that assesses actual risk at actual intakes reaffirmed the ADI the same week. Most sweetener coverage collapses that distinction, and most sweetener anxiety lives in the gap.

The US wrinkle is GRAS (Generally Recognized as Safe), the pathway by which newer entrants like monk fruit and allulose entered the market via industry-assembled safety dossiers rather than formal additive petitions. It's faster and lighter-touch, which is why the newest sweeteners are often the least studied, and why "no evidence of harm" for a recent GRAS entrant means less than it does for aspartame.

The rankings, as of now

Ranked by evidence rather than by naturalness, the field inverts the consumer intuition.

Tier 1: Allulose, stevia, monk fruit. Stevia's purified glycosides have a long record and no credible harm signal. Monk fruit has no red flags and the thinnest file, which is a weaker endorsement than it sounds. Allulose is the only sweetener with a case for active benefit: it blunts post-meal glucose, and human studies at 5 to 10 grams show modest, transient GLP-1 increases, with no established minimum effective dose and wide individual variation. 

Tier 2: Aspartame, sucralose, saccharin. The most-feared tier and the best-studied one. Real but modest signals exist, including a well-designed 2022 trial in which sucralose altered the microbiome and impaired glycemic response in a subset of participants.

Tier 3: Erythritol and xylitol, the sugar alcohols keto built. In a controlled intervention, 30 grams of erythritol, roughly a sugarless muffin's worth, raised blood levels more than 1,000-fold and enhanced multiple measures of platelet function, while an equivalent sugar dose did neither. Xylitol carries a parallel package of cohort associations with cardiovascular events plus platelet reactivity data, with the causal interpretation still being fought out in the journals. The fair caveats: the cohort studies never measured dietary intake, the body makes its own erythritol when metabolism deteriorates, and the highest-level participants in cohort data were older and sicker to begin with.

One practical note that follows from the tiers. Tabletop stevia and monk fruit products are typically bulked with erythritol, because milligrams of extract can't fill a packet. The front label sells Tier 1. The ingredient panel often delivers Tier 3.

What's coming

Three forces are redrawing the category.

The first is the engineered generation. Sweet proteins like brazzein and thaumatin, thousands of times sweeter than sugar and metabolized as protein rather than carbohydrate, are moving from curiosity to product via precision fermentation. Rare sugars beyond allulose, like tagatose, are in the same lane: molecules selected on purpose for metabolic behavior, a genuine break from the accident era. The open questions are cost curves and whether GRAS-era safety files will satisfy a public that just watched erythritol's halo crack.

The second is scrutiny migrating down the shelf. The erythritol and xylitol work established a template, circulating-metabolite cohorts plus platelet studies, that will be pointed at other ingredients. Expect the sugar alcohol complex to rotate out of "clean" formulations faster than the science strictly requires, because CPG reformulation runs on liability and perception, not on ADIs.

The third is the GLP-1 era, which changes the demand side. Current GLP-1 users report buying fewer sweet treats at a 61% clip, with sugary drinks among the biggest casualties. A shrinking appetite for sweetness shrinks the market for sweetness substitutes too. The category's next growth story is less "diet soda" and more "metabolically functional ingredient," which is exactly the positioning allulose and the sweet proteins are built for, and exactly where the marketing will outrun the evidence first.

Why You Should Care

The century-long pattern is that sweeteners get judged by their origin story rather than their data. "Chemical accident" molecules accumulated the deepest safety files in food science and still poll as the scariest thing in the aisle. "Natural" molecules got a pass, and the one that keto scaled to ubiquity is now the only sweetener with credible human evidence pointing the wrong way. The heuristic failed in both directions.

Nothing in this category has a long-term randomized trial with hard outcomes, which is why the WHO's recommendation against sweeteners for weight control was explicitly low-certainty. So hold the rankings loosely, read ingredient panels rather than front labels, and watch the engineered generation closely. The first era of this market was built on accidents. The next one is being designed, and the design targets are metabolic, which means the claims are about to get much bigger than the trials behind them.

Or copy and paste this link to others: {{rp_refer_url}}

Current Referral Count: {{rp_num_referrals}}